What are the best augmentation options for a patient with anxiety and depression who is still experiencing symptoms while taking 15mg of Lexapro (escitalopram)?

Augmentation Strategy for Lexapro 15mg with Persistent Anxiety and Depression

Increase escitalopram to 20mg daily and add bupropion SR 150-400mg as combination therapy, which achieves remission rates of approximately 50% compared to 30% with SSRI monotherapy alone. 1

Step 1: Optimize Current Escitalopram Dose

Before considering augmentation, the escitalopram dose must be maximized:

• Increase to 20mg daily (the FDA-approved maximum dose), as the patient is currently on a subtherapeutic 15mg dose 1
• Allow 8-12 weeks at 20mg before declaring treatment failure, as this is the minimum duration needed to assess full antidepressant response 2, 1
• Japanese studies demonstrate that 20mg produces statistically significant anxiety reduction compared to placebo, with sensitivity analyses showing benefit at both 10mg and 20mg doses 1

Critical pitfall to avoid: Switching medications or adding augmentation before allowing adequate trial duration (8-12 weeks at 20mg minimum) delays recovery and worsens outcomes 1

Step 2: Add Cognitive-Behavioral Therapy (CBT) Immediately

While optimizing medication dose, initiate CBT concurrently:

• Combination of SSRI with CBT demonstrates superior efficacy compared to medication alone for both anxiety and depression 1, 3
• CBT can be started immediately while titrating escitalopram, providing synergistic benefit 1
• The American Academy of Child and Adolescent Psychiatry emphasizes that combination therapy addresses both neurobiological and psychological components simultaneously 1

Step 3: Pharmacological Augmentation (If Inadequate Response After 8-12 Weeks at 20mg)

Primary Recommendation: Bupropion SR Augmentation

Add bupropion SR 150-400mg daily as the preferred pharmacological augmentation strategy:

• Significantly lower discontinuation rates due to adverse events compared to buspirone (12.5% vs 20.6%, p<0.001) 2, 1, 4
• The STAR*D trial demonstrated similar efficacy between bupropion and buspirone augmentation of citalopram (a closely related SSRI) 2, 1
• Additional benefit of lower sexual dysfunction rates compared to continuing SSRI monotherapy 1
• Start at 150mg daily and titrate to 300-400mg based on response and tolerability 2

Alternative Augmentation: Buspirone

If bupropion is contraindicated (seizure history, eating disorders):

• Start buspirone at 5mg twice daily, titrating to 20mg three times daily over 2-4 weeks 1, 4
• Allow 2-4 weeks for full therapeutic effect—unlike benzodiazepines, buspirone is not immediately effective 4
• STAR*D trial showed similar efficacy to bupropion but higher adverse event discontinuation rates 2, 1, 4

Critical pitfall: Expecting immediate results from buspirone leads to premature discontinuation; it requires 2-4 weeks to reach full effect 4

Step 4: Alternative Strategy If Augmentation Fails

Switch to SNRI

If no response after 8 weeks of optimized combination therapy:

• Switch to venlafaxine extended-release (37.5-225mg daily) or duloxetine (40-120mg daily) 1
• SNRIs demonstrate statistically significantly better response and remission rates than SSRIs in treatment-resistant depression with comorbid anxiety 1
• Implement gradual cross-titration when switching from escitalopram to minimize discontinuation symptoms 1

The American College of Physicians found no significant difference between switching versus augmenting strategies overall, but switching may be preferred if no partial benefit exists from escitalopram 2, 1

Critical Monitoring Requirements

Suicidality Monitoring

• Assess for suicidal ideation at every visit, particularly during the first 1-2 months after any treatment change, as suicide risk is greatest during this period 1
• Monitor for emergence of agitation, irritability, or unusual behavioral changes indicating worsening depression 1

Response Assessment

• Use standardized anxiety and depression rating scales (PHQ-9, GAD-7, HAM-D) every 2-4 weeks to objectively track symptoms 1
• Evaluate treatment response at 2-4 week intervals following dose adjustments 1

Cardiac Monitoring

• Do not exceed escitalopram 20mg daily without cardiac monitoring, as higher doses increase QT prolongation risk without additional benefit 1
• Baseline ECG may be warranted if cardiac risk factors exist 1

Duration of Continuation Therapy

Once remission is achieved:

• Continue treatment for 6+ months after first episode of major depression 1
• For recurrent depression (2+ episodes), consider years to lifelong maintenance therapy 1
• 24-week relapse prevention studies show 23% relapse with escitalopram versus 50-52% with placebo, demonstrating importance of long-term maintenance 1

What NOT to Do

• Do not add benzodiazepines for long-term management—they should only be used as short-term "bridging strategy" during initial weeks while antidepressant takes effect 3, 5
• Do not combine escitalopram with other serotonergic agents (MAOIs, multiple SSRIs) due to serotonin syndrome risk 1
• Do not make dose changes more frequently than every 2-4 weeks, as this prevents adequate assessment of therapeutic response and increases destabilization risk 1
• Do not switch medications before 8-12 weeks at maximum tolerated dose, as premature switching leads to missed opportunities for response 1